Parliamentary Search

Written question asked by Chi Onwurah (Labour) on Monday, 17 January 2022, in the House of Commons. It was due for an answer on Wednesday, 19 January 2022. It was answered by Edward Argar (Conservative) on Tuesday, 25 January 2022 on behalf of the Department of Health and Social Care.

Medical Technologies Directorate: Life Sciences

Question

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92932, what plans his Department has to ensure the Medical Technology Directorate supports progress on the Precondition for Success, set out in the Life Sciences Vision, to improve access to finance for innovative UK Life Sciences companies.

Answer

The Medical Technology Directorate is supporting the Life Sciences Vision by enhancing market arrangements on innovation and evidence; working with the Medicines and Healthcare products Regulatory Agency on the United Kingdom’s medical device regulations to ensure patient safety and influence international standards; enhancing data across the health system; and improving the resilience of the supply chain.

To attract investment, the MedTech strategy will outline plans to align clinical and commercial leadership to reduce complexities in channels for procurement and budgets. We have announced £5 billion to increase health-related research and invest in innovation. The Office for Life Sciences will set out plans to develop a globally competitive investment environment in the UK, where promising life science companies, including medical technology businesses, can access long-term capital.

Secondary information

Type
Written question
Reference
105518
Session
2021-22
Related items
Medical Technologies Directorate: Life Sciences
Monday, 20 December 2021
Written questions
House of Commons
Grouped for answer
Yes
Subjects
Business Finance Innovation Life sciences Medical Technologies Directorate
Link
View this Written question on www.parliament.uk